• Home
  • About IonChannelCentral

Ion channel News

Entries RSS | Comments RSS
  • Tags

    agonist amitiza Amlodipine Anesiva Angiotensin II AT1 antagonist AstraZeneca ca channel Calcium Channel chloride channel CIC-2 CIC2 cl channel Clevelox Clevidipine Cleviprex CV therapeutics Icagen Ion Channel KCa3.1 K Channel Licensing lidocaine lubiprostone Merck na channel Novartis phase II Potassium Channel preclinical Regulatory Research RU-0211 RU0211 Senicapoc Sodium channel SPI-0211 Sucampo takeda The Medicines Company TRPV1 UCB Vanilloid voltage gated VR1

Senomyx drug S3969 fully and reversibly activates human ENaC

Posted on April 26, 2008 by crimsoncanary

A paper in this weeks JBC describes how S3969 fully and reversibly activates the human epithelial sodium channel hENaC. S3969 interacts with the extracellular domain of the beta subunit.

Filed under: Ion Channel, Sodium channel | Tagged: enac, henac, na channel, s-3969, s3969, senomyx, Sodium channel

Clevidipine to enter new Phase III trial for Acute Hypertension and Intracerebral Hemorrhage »

Leave a Reply

Click here to cancel reply.

  • Calendar

    • April 2008
      M T W T F S S
          May »
       123456
      78910111213
      14151617181920
      21222324252627
      282930  
  • Blogroll

    • CrimsonCanary.com
    • IonChannelCentral
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer